Clinical Trial of bevacizumab in patients with retinopathy of prematurity

Clinical Trial of bevacizumab in patients with retinopathy of prematurity - MBROP

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2091220073

Enrollment

Registered

2011-10-16

Start date

2009-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity

Interventions

Intervention type:DRUG Name of intervention:bevacizumab Dose form / Japanese Medical Device Nomenclature:INJECTION Route of administration / Site of application:OPHTHALMIC Dose per administration:0.62

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with retinopathy of prematurity admitted in Miyazaki University Hospital

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
retinal status	—

Countries

Japan

Contacts

Public ContactMasumi Inadumi

School of Medicine, Miyazaki University

nobunaoi@gmail.com+81-985-85-1510

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026